Cyanotech (CYAN) Issues Revenue Results

Cyanotech (CYAN) Issues  Revenue Results

Cyanotech (NASDAQ:CYAN) released its quarterly earnings data on Monday, November 12th. The biotechnology company reported ($0.20) EPS for the quarter, Bloomberg Earnings reports. The business had revenue of $6.95 million during the quarter. Cyanotech had a negative net margin of 7.53% and a negative return on equity of 13.51%.

Cyanotech stock traded up $0.05 during midday trading on Wednesday, hitting $3.70. 636 shares of the stock were exchanged, compared to its average volume of 1,951. Cyanotech has a fifty-two week low of $3.08 and a fifty-two week high of $5.78. The company has a debt-to-equity ratio of 0.34, a quick ratio of 0.43 and a current ratio of 1.80.

Separately, TheStreet downgraded shares of Cyanotech from a “c” rating to a “d” rating in a report on Monday, August 13th.

About Cyanotech

Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. The company's products include Hawaiian BioAstin natural astaxanthin, a dietary antioxidant, which is used as a human nutraceutical and functional food ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye and joint health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids.

Recommended Story: Day Trading – Risk Worth the Reward?

Related posts

Leave a Comment